Fresenius Medical Care AG (NYSE:FMS) posted a healthy quarter with growth in sales and earnings driven by a 26 percent bump in international sales.
"We are particularly pleased with the success of our international region, given a persistently challenging business environment with the current debt crisis worldwide and the successful expansion of our clinic network in Asia-Pacific and Europe," CEO Dr. Ben Lipps said in prepared remarks.
The Waltham, Mass.-based dialysis treatment company saw a 6 percent increase in sales during the three months ended June 30, amounting to $3.2 million, compared to $2.3 million in sales during the same period last year.
Profits also increased, coming in at $261,000, or 86 cents per diluted share, a 5 percent boost from the $248,000 in earnings, or 83 cents per diluted share, for Q2 2010, according to a press release.
Fresenius, which is currently caught in a patent spat with Baxter International Inc. (NYSE: BAX), which is demanding $20 million over violations of a touch-screen dialysis machine patent, confirmed its outlook for the year at revenues above $13 billion and income between $1.07 billion and $1.09 billion.
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
Kensey Nash sinks hard in Q4
Kensey Nash Corp. (NSDQ:KNSY) saw a dramatic decline in the three months ended June 30. The Exton, Pa.-based regenerative medicine company posted a 15 percent decrease in sales to $18.7 million, compared to $21.9 million during the same period last year.
Company profits dove 50 percent to $2.9 million, or 34 cents per diluted share, compared to $5.9 million, or 60 cents per diluted share in Q4 of 2010.
Sales for the year sank 11 percent to $71.6 million to, or 23 cents per diluted share, from $80.6 million, or $1.78 per diluted share, for FY 2010.
Solos narrows losses
Solos Endoscopy Inc. (PINK:SNDY), which launched a revamped veterinary product line of endoscopic equipment early in July, narrowed losses on decreased sales in the three months ended June 30. The Boston, Mass.-based company posted a 19 percent decrease in sales to $91,865, compared to $113,148 during the same period last year.
Company losses narrowed 19 percent to $186,360, or a loss of 2 cents per diluted share, compared to $229,973 lost, or 82 cents kist per diluted share in Q2 of 2010.
ProUroCare tightens its belt
ProUroCare Medical Inc. (OTC:PUMD), a pre-revenue company tightened its belt in the three months ended June 30. The Eden Prairie, Minn.-based prostate imaging company posted a 28 percent decrease in operating losses to $377,134, compared to $529,159 in operating expenses during the same period last year.
Total losses narrowed 65 percent to $488,813, or 3 cents lost per diluted share, compared to $1.4 million, or 11 cents lost per diluted share in Q2 of 2010.